Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.55 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.56 |
| ▸ | PPIA | P62937 | 1/20 | 0.56 |
| ▸ | PPID | Q08752 | 1/20 | 0.56 |
| ▸ | PPIG | Q13427 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85523 | 0.98 | PPID (0.58) | PPIBPPIAPPIDPPIGLMNA | |
| SCHEMBL68851 | 0.88 | CYP4Z1 (0.62) | LMNAMAPTCYP4Z1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27427984 | 0.86 | LMNA (0.49) | PPIBPPIAPPIDPPIGLMNA | |
| Hydrochloric Acid SCHEMBL9259476 | 0.86 | CYP4F2 (0.51) | PPIBPPIAPPIDPPIGLMNA | |
| Hydrochloric Acid SCHEMBL8785068 | 0.85 | MAPT (0.54) | LMNACYP1A2MAPTCYP4Z1SMN1; SMN2 | |
| SCHEMBL10461745 | 0.84 | CYP4F2 (0.53) | PPIBPPIAPPIDPPIGLMNA | |
| SCHEMBL11038201 | 0.84 | CYP1A2 (0.47) | PPIBPPIAPPIDPPIGLMNA | |
| SCHEMBL19346039 | 0.83 | LMNA (0.48) | PPIBPPIAPPIDPPIGLMNA | |
| SCHEMBL480039 | 0.83 | CYP4Z1 (0.54) | LMNACYP1A2MAPTCYP4Z1SMN1; SMN2 | |
| SCHEMBL10299459 | 0.82 | CYP4Z1 (0.57) | LMNAMAPTCYP4Z1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63233963-A | — | — | None | — | — | JP | disclosed |
| US-20180141965-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2018-05-24 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| CN-102648178-A | Quinazoline derivatives | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| CN-101102818-A | Medicaments comprising carbonyl compounds, and the use thereof | MERCK PATENT GMBH (DE) | 2008-01-09 | — | — | CN | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| EP-0485158-A2 | Esters and amides of substituted phenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4873253-A | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-10-10 | — | — | US | disclosed |
| US-4839360-A | ANTIDEPRESSANTS; NERVOUS AND PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS | TANABE SEIYAKU CO., LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0298135-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-01-11 | — | — | EP | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
| JP-S63233963-A | PHENYLALANINE DERIVATIVE AND PROTEINASE INHIBITING AGENT | SHOWA DENKO KK | 1988-09-29 | — | — | JP | disclosed |
| EP-0270093-A2 | Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties | TANABE SEIYAKU CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3993763-A | ALPHA-(CYCLIC TERTIARY AMINO-PHENYL)-ALIPHATIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3936467-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | MAOA 527/4885PPARG 1652/4885GAA 1047/4885 |
| US-20180141965-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SPINT2, SERPINB1 | MAOA 655/4885PPARG 3856/4885GAA 162/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | MAOA 428/4885PPARG 640/4885GAA 660/4885 |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | MAOA 3100/4885PPARG 1996/4885GAA 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.